E2 ModeratePreliminaryPEM unclearCross-SectionalPeer-reviewedMachine draft
Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hypersomnia and cognitive disorders.
Nishikai, M, Tomomatsu, S, Hankins, R W et al. · Rheumatology (Oxford, England) · 2001 · DOI
Quick Summary
Researchers tested blood samples from ME/CFS and fibromyalgia patients to look for specific antibodies (immune proteins) that might be unique to these conditions. They found that about 13% of ME/CFS patients and 16% of fibromyalgia patients had antibodies against a protein called 68/48 kDa. Importantly, patients with these antibodies were more likely to experience severe sleep problems, memory issues, and trouble concentrating.
Why It Matters
This study suggests that certain ME/CFS patients may have a distinct immune signature involving specific autoantibodies, which could help identify a subgroup with particular symptom profiles. If validated, these antibodies could serve as a biological marker to improve diagnosis and enable more targeted research into the immune mechanisms underlying cognitive and sleep problems in ME/CFS.
Observed Findings
- Anti-68/48 kDa autoantibodies were present in 13.2% of CFS patients and 15.6% of primary fibromyalgia patients, but absent in healthy subjects and connective tissue disease patients without fibromyalgia.
- CFS patients with anti-68/48 kDa antibodies had significantly higher rates of hypersomnia compared to seronegative CFS patients (P<0.005).
- CFS patients with anti-68/48 kDa antibodies showed higher prevalence of short-term memory problems (P<0.07) and concentration difficulties (P<0.05) than seronegative patients.
- Anti-45 kDa autoantibodies were found in 37.1% of secondary fibromyalgia patients and 21.6% of psychiatric disorder patients, but were absent in controls.
Inferred Conclusions
- A subset of both CFS and primary fibromyalgia patients share a common immunological signature involving anti-68/48 kDa autoantibodies, suggesting a possible shared pathogenic mechanism.
- Anti-68/48 kDa autoantibodies may serve as a clinicoserologcal marker identifying CFS/FM patients with predominant hypersomnia and cognitive complaints.
- These autoantibodies could help define a distinct phenotypic subgroup within the CFS/FM disease spectrum that warrants further investigation.
Remaining Questions
- What is the biological function of the 68/48 kDa target protein, and how might autoantibodies against it impair cognition and sleep regulation?
- Does the presence of these antibodies precede disease onset, or do they develop as a consequence of illness?
What This Study Does Not Prove
This study does not prove that these autoantibodies *cause* ME/CFS or its cognitive symptoms—it only shows they are more common in affected patients. The cross-sectional design cannot establish causation or determine whether the antibodies arise before or after illness onset. It also does not explain the biological mechanism by which these antibodies might contribute to hypersomnia or cognitive dysfunction.
Tags
Symptom:Cognitive DysfunctionUnrefreshing SleepFatigue
Biomarker:AutoantibodiesBlood Biomarker
Method Flag:Small SampleExploratory OnlyMixed Cohort
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →